Adjuvant pembrolizumab extends RFS in high-risk melanoma
Source: Healio, June 2021
Pembrolizumab extended RFS compared with high-dose interferon or ipilimumab as adjuvant therapy for patients with high-risk melanoma, according to randomized phase 3 study results presented during the virtual ASCO Annual Meeting.
Pembrolizumab (Keytruda, Merck) also appeared better tolerated.
